从JAK-STAT信号通路探讨痹证宁对风寒湿痹型类风湿关节炎的作用机制
2020-06-21何东初张倩
何东初 张倩



【摘 要】目的:探讨痹证宁对风寒湿痹型类风湿关节炎JAK-STAT信号通路的影响及作用机制。方法:將70只Wistar大鼠按照随机数字表法分为空白对照组,模型对照组,痹证宁低、中、高剂量组(9,18,36 g·kg-1),甲氨蝶呤组(1 mg·kg-1)和中西医结合组(甲氨蝶呤1 mg·kg-1+痹证宁18 g·kg-1),每组10只。除空白对照组外,其余各组大鼠模拟风寒湿环境,采用Ⅱ型胶原诱导方法制备风寒湿痹型类风湿关节炎大鼠模型,各组大鼠给予相应药物干预。28 d后,观察大鼠关节肿胀度、关节滑膜组织白细胞介素-6(IL-6)含量、PIAS3、P-STAT3蛋白和JAK3、STAT3 mRNA表达情况。结果:痹证宁可显著降低风寒湿痹型类风湿关节炎模型大鼠的关节肿胀度,降低IL-6含量,抑制P-STAT3蛋白、JAK3和STAT3 mRNA过表达,增进PIAS3蛋白表达。结论:痹证宁有抗炎、免疫调节作用,其作用机制可能与抑制JAK-STAT信号通路的过度激活有关。
【关键词】 关节炎,类风湿;痹证宁;风寒湿痹;JAK-STAT信号通路
【ABSTRACT】Objective:To explore the effect of Bizheng Ning(痹证宁)on JAK-STAT signal pathwayin rheumatoid arthritis of wind-cold-dampness bi type and its mechanism.Methods:Seventy Wistar rats were randomly divided into a blank control group,a model control group,low,medium and high dose Bizheng Ning groups(9,18,36 g·kg-1),a methotrexate group(1 mg·kg-1)and a combination group(1 mg·kg-1 of methotrexate + 18 mg·kg-1 of Bizheng Ning)treated with Chinese and Western medicine.There were10 rats in each group.Except the blank control group,the other groups of rats were used to establish rheumatoid arthritis models of wind-cold-dampness bi type by the method of typeⅡ collagen induction.The rats in each group were given corresponding medicine intervention.After 28 days,the degree of joint swelling,the content of IL-6 in synovium tissue,PIAS3,the expressions of P-STAT3 protein,JAK3 and STAT3 mRNA were observed.Results:Bizheng Ning can significantly reduce the joint swelling and IL-6 content,inhibit the expressions of P-STAT3 protein,JAK3 and STAT3 mRNA,and increase the expression of PIAS3 protein.Conclusion:Bizheng Ning has anti-inflammatory and immunomodulatory effects,whose mechanism may be related to inhibiting the over activation of JAK-STAT signal pathway.
【Keywords】arthritis,rheumatoid;Bizheng Ning(痹证宁);wind-cold-dampnessbi;JAK-STAT signal pathway
类风湿关节炎(rheumatoid arthritis,RA)是一种因高风险遗传、环境暴露等多种因素导致关节滑膜炎的自身免疫性疾病,其病变可累及内脏器官结构[1]。目前,临床治疗RA的药物主要有非甾体抗炎药(NSAIDs)、改善病情抗风湿药(DMARDs)、糖皮质激素等,这些药物虽然能在一定程度上缓解病情,但需要长期服用,并且对患者的血细胞、肝肾功能都有不同程度的损害。随着疾病研究的深入,各种生物制剂相继出现,但其价格昂贵,且存在感染等不良反应[2-4]。因此,寻求高效低毒又个体化治疗的药物显得尤为重要。痹证宁是中国人民解放军中部战区总医院自拟中药复方,前期临床试验已证实本方可改善RA患者临床症状且不良反应少[5]。……
